Evidence map›Paper›PMID 41357269›Full record

ArticleHeart rhythm O22025

Artificial intelligence-enhanced electrocardiography and sudden death risk factors in cardiac arrest survivors diagnosed with hypertrophic cardiomyopathy.

William H Swain, John R Giudicessi, Jeffrey B Geske, Darrell B Newman, J Martijn Bos, Shahid Karim, Peter A Noseworthy, Zachi I Attia, Paul A Friedman, Adelaide M Arruda-Olson and 3 more

Abstract read
In one paragraph

Article in Heart rhythm O2, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

William H SwainDepartment of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
John R GiudicessiDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Jeffrey B GeskeDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Darrell B NewmanDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
J Martijn BosDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Shahid KarimDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Peter A NoseworthyDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Zachi I AttiaDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Paul A FriedmanDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Adelaide M Arruda-OlsonDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Michael J AckermanDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Steve R OmmenDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Konstantinos C SiontisDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The characteristics of patients with hypertrophic cardiomyopathy (HCM) who present with sudden cardiac arrest as the initial manifestation of the disease are not well known. Objective: The purpose of this study was to evaluate artificial intelligence-enhanced electrocardiography (AI-ECG) and sudden cardiac death (SCD) risk factors in patients with HCM presenting with sudden cardiac arrest (SCA). Methods: We identified patients within the Mayo Clinic enterprise (2001-2022) who were newly diagnosed with HCM after surviving SCA. Index clinical, electrocardiographic, and imaging characteristics were documented. Risk models for SCD in HCM were retrospectively applied. An AI-ECG algorithm designed for the detection of HCM was also applied to the patients' first ECG obtained at our institution. Results: Twenty-seven patients met the inclusion criteria. Eight patients (30%) had documented cardiac symptoms preceding SCA. Twenty-four patients (89%) had an abnormal electrocardiogram at index evaluation, and 16 (59%) had ≥1 SCD risk factor that could have qualified them for an implantable cardioverter-defibrillator if HCM had been diagnosed before SCA. Retrospective application of the European Society of Cardiology 5-year HCM Risk-SCD tool yielded a median score of 4.6% (interquartile range 3.2%-7.2%), with 12 patients (44%) having an estimated SCD risk of <4%, implying a low risk. AI-ECG indicated a high prediction score for HCM in 26 patients (96%), suggesting its potential utility as an early detector of the disease if applied before SCA. Conclusion: Among patients with SCA who were then newly diagnosed with HCM, conventional SCD risk factors were common but not universal in this post hoc assessment. AI-ECG may facilitate the early detection of HCM.

Indexed as

Hypertrophic cardiomyopathyImplantablecardioverter-defibrillatorSudden cardiac arrestVentricular fibrillationVentricular tachycardia

Identifiers

PMID41357269
PMCPMC12675116

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.